IBR2

IBR2 is a small-molecule inhibitor of the DNA repair protein RAD51. It acts by binding to RAD51, disrupting its multimerization and its interaction with the BRC repeats of BRCA2. This disruption impairs homologous recombination (HR) DNA double-strand break repair and accelerates the proteasome-mediated degradation of RAD51. Developed by researchers at the University of California, Irvine, IBR2 has demonstrated preclinical antiproliferative and apoptotic activity in various cancer cell lines, including triple-negative breast cancer and chronic myeloid leukemia (CML), and has shown synergy when combined with other chemotherapeutic and targeted agents.

Other names

(R)-1-(1H-indol-3-yl)-2-phenylmethanesulfonyl-1,2,3,4-tetrahydroisoquinoline2-(benzylsulfonyl)-1-(1H-indol-3-yl)-1,2-dihydroisoquinoline